JP7546549B2 - 組み合わせ療法 - Google Patents

組み合わせ療法 Download PDF

Info

Publication number
JP7546549B2
JP7546549B2 JP2021513254A JP2021513254A JP7546549B2 JP 7546549 B2 JP7546549 B2 JP 7546549B2 JP 2021513254 A JP2021513254 A JP 2021513254A JP 2021513254 A JP2021513254 A JP 2021513254A JP 7546549 B2 JP7546549 B2 JP 7546549B2
Authority
JP
Japan
Prior art keywords
kras
inhibitor
formula
pharmaceutical composition
dasatinib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021513254A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022500381A (ja
JP2022500381A5 (cg-RX-API-DMAC7.html
Inventor
エングストローム,ラーズ・ダニエル
アランダ,ルース・ウェイ
オルソン,ピーター
クリステンセン,ジェームズ・ゲイル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mirati Therapeutics Inc
Original Assignee
Mirati Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mirati Therapeutics Inc filed Critical Mirati Therapeutics Inc
Publication of JP2022500381A publication Critical patent/JP2022500381A/ja
Publication of JP2022500381A5 publication Critical patent/JP2022500381A5/ja
Priority to JP2024091743A priority Critical patent/JP2024133475A/ja
Application granted granted Critical
Publication of JP7546549B2 publication Critical patent/JP7546549B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021513254A 2018-09-10 2019-09-09 組み合わせ療法 Active JP7546549B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024091743A JP2024133475A (ja) 2018-09-10 2024-06-05 組み合わせ療法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862729169P 2018-09-10 2018-09-10
US62/729,169 2018-09-10
PCT/US2019/050224 WO2020055755A1 (en) 2018-09-10 2019-09-09 Combination therapies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024091743A Division JP2024133475A (ja) 2018-09-10 2024-06-05 組み合わせ療法

Publications (3)

Publication Number Publication Date
JP2022500381A JP2022500381A (ja) 2022-01-04
JP2022500381A5 JP2022500381A5 (cg-RX-API-DMAC7.html) 2022-09-16
JP7546549B2 true JP7546549B2 (ja) 2024-09-06

Family

ID=69776771

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021513254A Active JP7546549B2 (ja) 2018-09-10 2019-09-09 組み合わせ療法
JP2024091743A Pending JP2024133475A (ja) 2018-09-10 2024-06-05 組み合わせ療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024091743A Pending JP2024133475A (ja) 2018-09-10 2024-06-05 組み合わせ療法

Country Status (14)

Country Link
US (2) US20220040181A1 (cg-RX-API-DMAC7.html)
EP (2) EP4552631A3 (cg-RX-API-DMAC7.html)
JP (2) JP7546549B2 (cg-RX-API-DMAC7.html)
DK (1) DK3849534T3 (cg-RX-API-DMAC7.html)
ES (1) ES3017461T3 (cg-RX-API-DMAC7.html)
FI (1) FI3849534T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20250480T1 (cg-RX-API-DMAC7.html)
HU (1) HUE071715T2 (cg-RX-API-DMAC7.html)
LT (1) LT3849534T (cg-RX-API-DMAC7.html)
PL (1) PL3849534T3 (cg-RX-API-DMAC7.html)
PT (1) PT3849534T (cg-RX-API-DMAC7.html)
RS (1) RS66727B1 (cg-RX-API-DMAC7.html)
SI (1) SI3849534T1 (cg-RX-API-DMAC7.html)
WO (1) WO2020055755A1 (cg-RX-API-DMAC7.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3112043A1 (en) * 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
US12208099B2 (en) * 2018-09-10 2025-01-28 Mirati Therapeutics, Inc. Combination therapies
CN114616232B (zh) * 2019-09-06 2026-05-05 正大天晴药业集团南京顺欣制药有限公司 氮杂环庚烷并嘧啶类衍生物及其医药用途
US12122787B2 (en) 2019-09-20 2024-10-22 Shanghai Jemincare Pharmaceuticals Co., Ltd Fused pyridone compound, and preparation method therefor and use thereof
BR112022006394A2 (pt) 2019-10-02 2022-07-26 Tolremo Therapeutics Ag Derivados heterocíclicos, composições farmacêuticas e seu uso no tratamento ou melhora do câncer
US20230257374A1 (en) * 2019-10-10 2023-08-17 Innovent Biologics (Suzhou) Co., Ltd. Novel kras g12c protein inhibitor, preparation method therefor, and use thereof
WO2021085653A1 (en) 2019-10-31 2021-05-06 Taiho Pharmaceutical Co., Ltd. 4-aminobut-2-enamide derivatives and salts thereof
WO2021108682A1 (en) 2019-11-27 2021-06-03 Turning Point Therapeutics, Inc. Combination therapy involving diaryl macrocyclic compounds
EP4067343A4 (en) 2019-11-29 2024-01-03 Taiho Pharmaceutical Co., Ltd. NEW PHENOLIC COMPOUND OR SALT THEREOF
WO2021215544A1 (en) 2020-04-24 2021-10-28 Taiho Pharmaceutical Co., Ltd. Kras g12d protein inhibitors
US12702658B2 (en) 2020-04-24 2026-08-11 Taiho Pharmaceutical Co., Ltd. Anticancer combination therapy with N-(1-acryloyl-azetidin-3-yl)-2-((1H-indazol-3-yl)amino)methyl)-1H-imidazole-5-carboxamide inhibitor of KRAS-G12C
TW202144349A (zh) * 2020-04-30 2021-12-01 大陸商上海科州藥物研發有限公司 作為kras抑制劑的雜環化合物的製備及其應用方法
WO2021231526A1 (en) * 2020-05-13 2021-11-18 Incyte Corporation Fused pyrimidine compounds as kras inhibitors
CN113683616B (zh) * 2020-05-18 2025-12-30 广州百霆医药科技有限公司 Kras g12c突变蛋白抑制剂
WO2021260110A1 (en) 2020-06-25 2021-12-30 Tolremo Therapeutics Ag Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of fibrotic disease
AU2021298154A1 (en) * 2020-06-25 2023-02-23 Tolremo Therapeutics Ag Combination of a CBP/p300 bromodomain inhibitor and a KRAS inhibitor for the treatment of cancer
WO2022109487A1 (en) 2020-11-23 2022-05-27 Merck Sharp & Dohme Corp. Spirocyclic-substituted 6,7-dihydro-pyrano[2,3-d]pyrimidine inhibitors of kras g12c mutant
WO2022204112A1 (en) 2021-03-22 2022-09-29 Incyte Corporation Imidazole and triazole kras inhibitors
CA3212085C (en) 2021-04-07 2025-02-11 Tolremo Therapeutics Ag HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR RELIEF OF CANCER
CN113429405A (zh) * 2021-06-10 2021-09-24 都创(上海)医药开发有限公司 Mrtx849化合物的晶型及其制备方法和用途
CN117940132A (zh) * 2021-06-24 2024-04-26 医睿世康药业研发公司 Erk1/2和kras g12c抑制剂组合疗法
WO2023283213A1 (en) 2021-07-07 2023-01-12 Incyte Corporation Tricyclic compounds as inhibitors of kras
CA3224841A1 (en) 2021-07-14 2023-01-19 Zhenwu Li Tricyclic compounds as inhibitors of kras
CA3229855A1 (en) 2021-08-31 2023-03-09 Incyte Corporation Naphthyridine compounds as inhibitors of kras
KR20240114793A (ko) 2021-11-05 2024-07-24 프론티어 메디슨즈 코포레이션 Kras g12c 억제제
KR20260096846A (ko) 2023-10-20 2026-06-24 머크 샤프 앤드 돔 엘엘씨 Kras 단백질의 소분자 억제제
CN122459678A (zh) 2023-12-29 2026-07-24 百时美施贵宝公司 KRAS抑制剂与Treg耗竭剂的组合疗法
CN119607214B (zh) * 2025-02-17 2025-06-20 四川大学华西医院 Src抑制剂联合kras-g12c抑制剂用于制备治疗kras-g12c突变型肺癌的药物中的应用及药物组合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017528488A (ja) 2014-09-18 2017-09-28 アラクセス ファーマ エルエルシー がんの処置のための併用療法
WO2017201161A1 (en) 2016-05-18 2017-11-23 Mirati Therapeutics, Inc. Kras g12c inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2452603A1 (en) 2001-07-03 2003-01-16 Vertex Pharmaceuticals Incorporated Isoxazolyl-pyrimidines as inhibitors of src and lck protein kinases
US20040014676A1 (en) 2001-07-09 2004-01-22 Ramalinga Dharanipragada SRC kinase inhibitors useful for treating osteoporosis
EP2258371A1 (en) 2001-08-10 2010-12-08 Novartis AG Use of c-Src inhibitors alone or in combination with STI571 for the treatment of leukaemia
RU2350618C2 (ru) 2002-11-04 2009-03-27 Астразенека Аб ПРОИЗВОДНЫЕ ХИНАЗОЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ Src ТИРОЗИНКИНАЗЫ
US8283441B2 (en) 2006-10-31 2012-10-09 University Of Toledo Na+K+-ATPase-specific peptide inhibitors/activators of SRC and SRC family kinases
CN101677979A (zh) 2007-04-19 2010-03-24 利奥制药有限公司 Src家族激酶抑制剂
CN104230901A (zh) 2008-09-15 2014-12-24 加利福尼亚大学董事会 用于调节ire1、src和abl活性的方法和组合物
US9090617B1 (en) 2011-08-03 2015-07-28 National Taiwan University Agonists of Src homology-2 containing protein tyrosine phosphatase-1 and treatment methods using the same
PL2739139T3 (pl) 2011-08-03 2020-06-15 National Taiwan University Agoniści białkowej fosfatazy tyrozynowej 1 zawierającej domeny homologii z src 2 i sposoby leczenia z ich zastosowaniem
CA2944198C (en) 2013-04-26 2021-11-16 Indiana University Research & Technology Corporation Hydroxyindole carboxylic acid based inhibitors for oncogenic src homology-2 domain containing protein tyrosine phosphatase-2 (shp2)
US9862701B2 (en) * 2014-09-25 2018-01-09 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
JP7327802B2 (ja) * 2017-01-26 2023-08-16 アラクセス ファーマ エルエルシー 縮合ヘテロ-ヘテロ二環式化合物およびその使用方法
CA3082579A1 (en) 2017-11-15 2019-05-23 Mirati Therapeutics, Inc. Kras g12c inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017528488A (ja) 2014-09-18 2017-09-28 アラクセス ファーマ エルエルシー がんの処置のための併用療法
WO2017201161A1 (en) 2016-05-18 2017-11-23 Mirati Therapeutics, Inc. Kras g12c inhibitors

Also Published As

Publication number Publication date
PL3849534T3 (pl) 2025-05-12
LT3849534T (lt) 2025-05-12
EP3849534A1 (en) 2021-07-21
EP4552631A3 (en) 2025-07-02
JP2022500381A (ja) 2022-01-04
US20220040181A1 (en) 2022-02-10
JP2024133475A (ja) 2024-10-02
HUE071715T2 (hu) 2025-09-28
WO2020055755A1 (en) 2020-03-19
EP3849534A4 (en) 2022-06-22
DK3849534T3 (da) 2025-05-19
SI3849534T1 (sl) 2025-05-30
FI3849534T3 (fi) 2025-05-15
ES3017461T3 (en) 2025-05-13
PT3849534T (pt) 2025-04-01
US20250213579A1 (en) 2025-07-03
EP3849534B1 (en) 2025-03-05
HRP20250480T1 (hr) 2025-06-20
RS66727B1 (sr) 2025-05-30
EP4552631A2 (en) 2025-05-14

Similar Documents

Publication Publication Date Title
JP2024133475A (ja) 組み合わせ療法
JP2025098159A (ja) 組み合わせ療法
JP2025000632A (ja) 組み合わせ療法
JP7546548B2 (ja) 組み合わせ療法
JP2025000629A (ja) 組み合わせ療法
JP2025000630A (ja) 組み合わせ療法
JP2024540839A (ja) Kras g12d阻害剤とshp-2阻害剤との併用療法
JP2024537140A (ja) Kras g12d阻害剤とsos1阻害剤との併用療法
JP2024537136A (ja) KRAS G12D阻害剤と汎ErbBファミリー阻害剤との併用療法
JP2024521788A (ja) 併用療法
JP2025512999A (ja) Sos1阻害剤及びegfr阻害剤を含む併用療法
US20250177399A1 (en) Combination therapies
JP2025513802A (ja) Sos1阻害剤及びmek阻害剤を含む併用療法
JP2025531491A (ja) 併用療法
HK40109896A (en) Combination therapies of kras g12d inhibitors with shp-2 inhibitors
HK40109895A (en) Combination therapies of kras g12d inhibitors with sos1 inhibitors
EA044829B1 (ru) Способы комбинированной терапии

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220908

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220908

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230808

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231107

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240606

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240626

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240806

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240827

R150 Certificate of patent or registration of utility model

Ref document number: 7546549

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150